APRE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
-100.0%
3.3K
+80.6%
1.8K
-98.4%
118.1K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
3.3K
+80.6%
1.8K
-98.4%
118.1K
Operating Expenses
4.0M
+17.5%
3.4M
+29.6%
2.6M
-15.2%
3.1M
-11.0%
3.5M
R&D
2.5M
+52.8%
1.6M
+59.7%
1.0M
-38.4%
1.6M
-14.3%
1.9M
SG&A
1.6M
-13.7%
1.8M
+11.1%
1.6M
+10.6%
1.5M
-7.1%
1.6M
Operating Income
-4032180
-17.5%
-3430412
-29.8%
-2643093
+15.2%
-3117388
+8.0%
-3387773
EBITDA
-4026434
-17.6%
-3424984
-29.8%
-2637664
+15.2%
-3111959
+8.0%
-3382345
Net Income
-3591304
-9.2%
-3287917
-33.9%
-2455630
+17.4%
-2972410
+8.2%
-3238870
EPS (Basic)
$-0.07
+68.2%
$-0.22
+31.3%
$-0.32
+31.9%
$-0.47
+11.3%
$-0.53
EPS (Diluted)
$-0.07
+68.2%
$-0.22
+31.3%
$-0.32
+31.9%
$-0.47
+11.3%
$-0.53
Shares (Diluted)
53.5M
+264.2%
14.7M
+90.6%
7.7M
+20.9%
6.4M
+4.8%
6.1M
Aprea Therapeutics (APRE) โ€” Financials